Galcanezumab for preventing migraine: Final appraisal document

DRAFT guidance recommends galcanezumab as an option for preventing migraine in adults, only if: they have 4 or more migraine days a month, at least 3 preventive drug treatments have failed and the company provides it according to the commercial arrangement.

Source:

National Institute for Health and Care Excellence